A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess Bioequivalence of a New Tapentadol Extended-Release (TRF) 250-mg Tablet With Respect to a Tapentadol Extended-Release (PR2) 250-mg Tablet Under Fasted Conditions in Healthy Subjects
Latest Information Update: 19 Nov 2013
At a glance
- Drugs Tapentadol (Primary)
- Indications Cancer pain; Diabetic neuropathies; Neuropathic pain; Pain
- Focus Pharmacokinetics
- Sponsors Johnson & Johnson
- 19 Nov 2013 New trial record